CD34 and hematopoietic and lymphoid system neoplasm: For each TF, we measured how well the DISCERN score of a gene can predict the differential binding of the TF in active enhancer regions (marked by H3K27Ac) within 15kbs of the transcription start site (TSS) of the gene (Fig 5A–5C) and 5kb of the gene between blood cancer and normal cell lines (NB4 and CD34+) (S3A–S3C Fig).